Athersys Inc. (NASDAQ:ATHX) fell 2.2% during mid-day trading on Thursday . The stock traded as low as $2.16 and last traded at $2.21, with a volume of 349,642 shares. The stock had previously closed at $2.26.

Several brokerages recently issued reports on ATHX. Maxim Group reissued a “buy” rating on shares of Athersys in a research note on Sunday, May 8th. Zacks Investment Research raised Athersys from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research note on Monday, July 11th. Finally, TheStreet raised Athersys from a “sell” rating to a “hold” rating in a research note on Tuesday, May 31st.

The stock has a market cap of $190.66 million and a P/E ratio of 226.00. The firm has a 50-day moving average of $2.24 and a 200 day moving average of $1.96.

Athersys (NASDAQ:ATHX) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.14. During the same period last year, the business posted ($0.16) earnings per share. The firm earned $15.45 million during the quarter, compared to analyst estimates of $1.85 million. The firm’s quarterly revenue was up 2016.4% on a year-over-year basis. On average, equities research analysts anticipate that Athersys Inc. will post ($0.23) earnings per share for the current year.

In other news, COO William Lehmann, Jr. sold 25,000 shares of Athersys stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of $2.17, for a total value of $54,250.00. Following the completion of the sale, the chief operating officer now directly owns 279,017 shares of the company’s stock, valued at approximately $605,466.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.